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Objective: Sensorineural hearing loss leads to the progressive degeneration of spiral ganglion 
cells (SGC). Next to postoperative fibrous tissue growth, which should be suppressed to assure 
a close nerve–electrode interaction, the density of healthy SGC is one factor that influences the 
efficiency of cochlear implants (CI), the choice of treatment for affected patients. Rolipram, a 
phosphodiesterase-4 inhibitor, has proven neuroprotective and anti-inflammatory effects and 
might also reduce SGC degeneration and fibrosis, but it has to pass the cellular membrane to 
be biologically active.
Methods: Lipidic nanocapsules (LNC) can be used as biodegradable drug carriers to increase 
the efficacy of conventional application methods. We examined the biological effects of 
  rolipram and LNC’s core encapsulated rolipram on SGC and dendritic cell (DC) tumor necrosis 
factor-α (TNF-α) production in vitro and on SGC survival in systemically-deafened guinea 
pigs in vivo.
Results: Our results prove that rolipram does not have a beneficial effect on cultured SGC. 
Incorporation of rolipram in LNC increased the survival of SGC significantly. In the DC study, 
rolipram significantly inhibited TNF-α in a dose-dependent manner. The rolipram-loaded 
LNC provided a significant cytokine inhibition as well. In vivo data do not confirm the in vitro 
results.
Conclusion: By transporting rolipram into the SGC cytoplasm, LNC enabled the 
neuroprotective effect of rolipram in vitro, but not in vivo. This might be due to dilution 
of test substances by perilymph or an inadequate release of rolipram based on differing in 
vivo and in vitro conditions. Nevertheless, based on in vitro results, proving a significantly 
increased neuronal survival when using LNC-rolipram compared to pure rolipram and pure 
LNC application, we believe that the combination of rolipram and LNC can potentially 
reduce neuronal degeneration and fibrosis after CI implantation. We conclude that rolipram 
is a promising drug that can be used in inner ear therapy and that LNC have potential as an 
inner ear drug-delivery system. Further experiments with modified conditions might reveal 
in vivo biological effects.
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In industrialized nations, sensorineural hearing loss is a common disease and is   usually 
caused by a primary loss of auditory hair cells, which are the inner ear’s sensory cells. 
In addition to hereditary factors, acquired causes, such as increased noise exposure 
or the application of ototoxic drugs, play a crucial role in the development of sen-
sorineural hearing loss.1,2
An effective treatment for damaged hair cells or for the regeneration of already 
degenerated sensory cells of the inner ear in humans is not yet possible. Instead, the 
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prosthetic forms of therapy are performed to replace the dam-
aged organ’s function. Severely impaired and deaf patients 
are treated by implantation of electronic inner ear prostheses 
called cochlear implants. Deaf patients treated with cochlear 
implants gain a renewed sense of hearing and have a greater 
opportunity to communicate using audible speech.3 This leads 
to improved social integration and a significant increase in 
the patient’s quality of life.
Cochlear implants use a multichannel electrode that is 
inserted into the scala tympani to replace the function of 
the missing hair cells. Through the formation and trans-
mission of spiral ganglion cell (SGC) action potentials, 
an artificially-generated sound impression is achievable. 
However, following the primary loss of hair cells, a progres-
sive decrease in SGC density is observed.4 This is caused 
by missing electrical and neurotrophic stimulation, as well 
as other forms of stimulation.5,6 To achieve better speech 
recognition with cochlear implants, a high number of SGC 
must be ensured.6
A large number of neurotrophic factors have a protec-
tive effect on SGC after primary hair cell loss. The systemic 
treatment of inner ear diseases is complicated by the presence 
of the blood–cochlear barrier. Adequate drug levels are only 
reached through the application of very high drug doses, 
which leads to an increased risk of side effects. Through local 
application of neurotrophic factors, the progressive degenera-
tion of SGC may be decreased. Important representatives of 
this substance group are brain-derived neurotrophic factor 
(BDNF), glial cell line-derived neurotrophic factor, and 
fibroblast growth factor.7,8 Nevertheless, continuous therapy 
is necessary because previous studies detected a progressive 
reduction of SGC after the cessation of therapeutical appli-
cation of BDNF.9 The first attempts to produce continuous 
drug-delivery systems were realized using osmotic pumps. 
These pumps allowed continuous application periods into the 
inner ear for weeks. Because of delivery time limitations and 
the necessity of pump changes that would allow for longer 
application duration, this approach is not feasible for human 
therapeutic applications.
Another option for chronic neurotrophic treatment is gene 
therapy. By introducing the gene sequences of neurotrophic 
factors to the cellular nucleus, the transfected cells may 
provide a sustainable endogenous production of neuropro-
tective substances.10,11 Via viral gene transfer, these factors 
were already implemented in the inner ear, although an 
expression of the introduced sequences did not demonstrate 
cell-specific gene transfer.12,13 Furthermore, only a temporary 
expression of about 3 weeks was achieved, which is not 
desirable in terms of long-term therapy.14 In addition, the 
use of viral vectors has considerable disadvantages, such as 
potential infection and the ability to trigger inflammatory or 
immunological processes.15
In addition to the viral vectors, artificially manufactured 
nanoparticles offer a promising ability to transport drugs and 
gene sequences with the ability of cargo release over a long 
period of time. Today, a variety of manufactured nanopar-
ticles, which consist of organic and inorganic parts, can be 
assembled. In addition to their common uses in industry, a 
wide range of applications in health and medicine are achiev-
able using nanoparticles.16 The advantages of nanoparticles 
are the impossibility of infection and the production of 
biodegradable scaffolds, for which a low response of the 
immune system is expected. Furthermore, nanoparticles can 
be produced inexpensively. By considering the property of the 
production of biological building principles, nanoparticles are 
ideal for the transport of medical drugs or genes. In addition 
to the transport function, it is possible to modify the surface 
of nanoparticles with specific receptors so that they will 
selectively bind to specific cells. The use of nanoparticles as 
a targeted treatment of specific cell populations results in a 
significant reduction of side effects.16
Recent research proved that fluoresceine-5-isothiocyanate 
(FITC)-labeled lipidic nanocapsules (LNC), locally inserted 
into the scala tympani of guinea pigs, infiltrated cell populations 
of the inner ear without causing functional or anatomical dam-
age.17 Those data were the first to demonstrate the ability of 
drug-unloaded LNC to enter inner ear cells. However, LNC-
mediated drug delivery was not examined in that study.
Besides the density of healthy SGC, the optimal effective-
ness of cochlear implants is influenced by another important 
factor. In the postoperative onset of foreign body reaction, the 
organism encapsulates the implant through the production 
of fibrous tissue growth. This results in decreased nerve–
electrode interaction, increased spread of neuronal excitation, 
reduced frequency selectivity, and increased impedances.18
Rolipram, an intracellular-acting phosphodiesterase-4 
inhibitor, showed neuroprotective properties in former 
studies.19,20 Furthermore, anti-inflammatory effects have also 
been proven in animal models.21 We hypothesize that rolip-
ram can potentially protect SGCs and reduce inflammatory 
reactions. If applied systemically, intravenously, or orally, 
rolipram has a bioavailability of 74%–77%.22 However, due 
to the blood–brain barrier, systemically-applied drugs that are 
used for inner ear treatment must be administered in such high 
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dosages to have a biological effect on their target cells in the 
inner ear, that side effects may occur. To avoid   massive side 
effects, local treatment of the inner ear is favored. In order to 
decrease the drugs applied locally to the inner ear, a targeted 
drug delivery is preferable. By encapsulating rolipram into a 
vehicle, such as LNC, a targeted drug delivery may be real-
ized in the future. This will decrease the amount of drugs 
that are needed for human therapy. In the inner ear, a targeted 
drug delivery will lead to a significant dosage reduction and, 
as a result, to a lower risk of side effects when compared 
to systemic treatment. Additionally, the lower dose is also 
economically beneficial. We hypothesize that LNC provide 
a feasible drug-delivery system that can be used to transport 
rolipram into the cytoplasm. Once in the cytoplasm, rolipram 
will be released and induce its biological effects.
This study examines the effect of rolipram and rolipram 
encapsulated in LNC on the survival rate, soma diameter, 
and neurite length of neonatally-harvested SGC in order to 
determine whether the drug’s effect is increased using LNC 
as a drug-delivery system.
Furthermore, the effect of rolipram and the combination 
of LNC and rolipram is evaluated on the tumor necrosis 
factor-α (TNF-α) secretion of lipopolysaccharide (LPS)-
stimulated dendritic cells (DC). This experiment indirectly 
provides information about the release of the payload and 
may demonstrate the potential of LNC as a delivery system 
for rolipram. Additionally, the results provide further insight 
into the anti-inflammatory effect of rolipram. This effect is 
due to the key role that TNF-α plays in the proinflammatory 
processes, which is appreciable in reducing postoperative 
reactions on cochlear implants.
Based on in vitro results, we performed experiments on 
systemically deafened guinea pigs in order to examine LNC’s 
suitability for rolipram delivery in vivo.
Materials and methods
Lipidic nanocapsules
In order to formulate LNC, the laboratory “Ingénierie de la 
Vectorisation Particulaire”, University of Angers (Angers, 
France) used a novel phase inversion-based method.23 The 
nanoparticles, which consisted of a liquid core, were sur-
rounded by a cohesive surfactant layer at the oil-aqueous 
interface (Figure 1A). The lipophilic Labrafac® WL 1349 
(Gattefossé SA, Saint-Priest, France), which is comprised 
of capric and caprylic acid triglycerides, was used to obtain 
the oily phase of the particles, whereas the aqueous phase 
included NaCl (Prolabo, Fontenay-sous-Bois, France) that 
was dissolved in Milli-Q-plus® purified water (Millipore, 
Billerica, MA). Hence, the LNC preparation required two 
tensioactive surfactants: Lipoïd® S75-3 (Lipoïd GmbH, 
Ludwigshafen, Germany), a soybean lecithin made of 
phosphatidylcholine (69%), phosphatidylethanolamine 
(10%), and other phospholipids, and Solutol® HS 15 (BASF, 
  Ludwigshafen, Germany), a composition of free polyeth-
ylene glycol (PEG) 660 and PEG 660-hydroxystearate. In 
order to prepare LNC with a mean diameter of 50 nm, the 
compounds were used in the following amounts: 1.028 g 
Labrafac®, 0.075 g Lipoïd®, 0.846 g Solutol®, 0.089 g 
NaCl, and 2.962 g pure water. Magnetic stirring (200 rpm) 
at room temperature resulted in an oil-in-water emulsion of 
all compounds. A progressive heating rate of 4°C/minute 
obtained the inverted phase (water-in-oil) at a temperature 
AB C
Labrafac®
Mixture of Lipoïd® and Solutol®
DSPE-PEG2000-amino
FITC
Rolipram
Figure 1 (A) Lipidic nanocapsule; (B) lipidic nanocapsule labeled with FITC, and (C) lipidic nanocapsule with rolipram encapsulation and FITC label.
Abbreviations: DSPE-PEG2000-amino, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(PEG)2000]; FITC, fluorescein isothiocyanate.
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of 85°C, with a phase inversion zone of approximately 70°C. 
This phase inversion zone corresponded to a microemulsion 
state and three temperature cycles, ranging from 60°C to 
85°C, were performed to ensure a stable oil-in-water emul-
sion. The LNC formulation was accomplished using a fast 
cooling-dilution process during the phase inversion zone, 
with 12.5 mL cold water in a ratio of 1:2.5. The LNC that 
were obtained had a diameter of 50 nm. For this purpose, 
the dilution was stirred for 5 minutes at 2°C.
To encapsulate rolipram (Sigma-Aldrich, Lyon, France), 
the drug was added before starting the three temperature 
cycles at a concentration of 1 mg/mL in Labrafac®.
The LNC surface was modified using a 1,2-distearoyl-
sn-glycero-3-phosphoethanolamine-N-[amino(PEG)2000] 
(DSPE-PEG2000-amino) post-insertion process. 1.75 mL 
LNC (1017 particles/mL) were incubated with a 1.25 mL 
aqueous micellar solution (15 mg/mL) of DSPE-PEG2000-
amino (Avanti®; Polar Lipids Inc, Alabaster, AL) for 
90 minutes at 60°C.24 The obtained suspension was vor-
texed every 15 minutes and quenched in ice water for 
60 seconds.
FITC-labeling of the LNC was performed with FITC 
(Figure 1B) purchased from Sigma-Aldrich. 1 mL of FITC 
(2 mg/mL) was added to the 2.95 mL LNC suspension. By 
adding an appropriate amount of 0.1 M Na3PO4, the pH was 
increased to 9. The sample, which was placed in a water bath 
and protected from light, was stirred at a temperature of 37°C 
for 45 minutes before being cooled down in an ice bath for 
3 minutes to stop the process.
In order to separate the free FITC from the labeled LNC 
size, exclusion chromatography on a Sephadex G-25 column 
(Pharmacia, Uppsala, Sweden) was executed. Fluorescence 
spectroscopy (FITC detection), as well as turbidity at 680 nm 
(LNC detection), was measured for each fraction. Integrity 
control of the LNC was performed by size measuring using 
a dynamic light scattering (DLS) procedure on the fractions 
that contained the particles.
DLS analysis and electrokinetic measurements indicated 
a hydrodynamic diameter of 52 ± 5 nm and a ζ-potential 
of −50 ± 10 mV . Finally, the concentration of the LNC solu-
tion was 4 × 1015 particles/mL.
For rolipram loading in the LNC, as well as for the 
modification by FITC (Figure 1C), the purification step was 
modified. After the grafting step, the mixture was dialyzed 
(MWCO 15 kDa) against pure water over night and the con-
centration was adjusted so as to obtain 4 × 1015 particles/mL. 
Hydrodynamic diameter and ζ-potential were checked and 
were found to be comparable with those obtained by LNC 
without rolipram.
In vitro experiments
Spiral ganglion cell culture
The dissociation of SGC from 3–5-day-old Sprague–Dawley 
rats was performed in accordance with the German law on 
protecting animals (§4/03). Before cell preparation, 96-mul-
tiwell culture plates (Nunc GmbH, Wiesbaden, Germany) 
were sequentially coated with polyornithine (Sigma, St, 
Louis, MO) and laminin (Invitrogen, Karlsruhe, Germany).25 
A total number of 1.5 × 104 cells were seeded per well in 
100 µL of modified panserin-based media.   Panserin (15 mL) 
was supplemented with 375 µL 1 M HEPES (Sigma, Stein-
heim, Germany), 275 µL phosphate-buffered saline (PBS; 
Invitrogen), 225 µL penicillin (Grünenthal, Aachen, Ger-
many), 82.5 µL glucose (30% in PBS), 35 µL insulin (Invit-
rogen), and 15 µL N2-supplement (Invitrogen) to prepare the 
media. The following experimental groups were performed 
in different concentrations: LNC labeled with FITC (LNC–
FITC), rolipram (rolipram; TOCRIS Bioscience, Ellisville, 
MO), and LNC–FITC with rolipram (LNC–FITC–rolipram). 
BDNF (50 ng/mL; R&D Systems, Wiesbaden, Germany) was 
used as a positive control.
Rolipram  was  used  in  concentrations  of  38  ng 
(1:50 dilution, n = 20), 19 ng (1:100 dilution, n = 20), 9.5 ng 
(1:200 dilution, n = 20), and 6.3 ng (1:300 dilution, n = 20) 
per 0.1 mL medium. The stock solution of LNC contained 
45 mg/mL (4.2 × 1015 LNC/mL) FITC-labeled LNC and 
19 µg/mL rolipram, respectively. The used dilutions con-
tained 0.9 mg/mL LNC (1:50 dilution), 0.45 mg/mL LNC 
(1:100 dilution), 0.225 mg/mL LNC (1:200 dilution), and 
0.15 mg/mL LNC (1:300 dilution).
After 48 hours cultivation time at 37°C and 5% CO2, cells 
were fixed with 1:1 methanol/acetone. Immunochemical stain-
ing with 200-kD neurofilament antibodies (Vectastain ABC 
Kit ELITE Mouse IgG; Vector Laboratories,   Burlingame, 
CA) enabled a clear identification of SGC. Untreated SGC, 
cultured with supplemented panserin only, served as a negative 
control. In order to determine the absolute number of seeded 
SGC, the seeding control was fixed after 4 hours. The mean 
of positive 200-kD-stained cells of the seeding control was 
set as 100%.
Vital SGC were defined as positive-stained neurons that 
showed a neurite outgrowth of at least three soma diameters. 
From five different fields of view within each well, one 
neuron was selected for the purpose of measuring the length 
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of the neuron and the neurite as described previously.26 Cell 
survival rate was determined by the number of vital neurons 
in correlation to the seeding control data.
SGC culture: investigation of LNC–FITC  
neuroprotective effect
The first SGC in vitro test revealed the neuroprotective poten-
tial of the LNC–FITC nanoparticles (Figure 3A), even though 
they were not loaded with the payload rolipram. A second 
test was performed to verify whether the nanoparticle itself 
or the fluorescein FITC had a positive effect on the SGC 
survival of the drug-unloaded LNC–FITC particles.
LNC–FITC nanoparticles were added to the SGC culture 
as described above in three different concentrations (1:100, 
1:200, 1:300 dilution of stock solution of 45 mg/mL LNC). 
LNC Blank particles (LNC without FITC labeling) were 
added in an analogous procedure. Furthermore, BDNF 
50 ng/mL-treated cells were used as a positive control. The 
cell culture medium of the seeding and the negative control 
remained untreated.
SGC were seeded in a mean density of 1.5 × 104 (247.3 ± 
59.8 SGC in seeding control [mean ± standard deviation]; 
n = 6). In three independently performed experimental set-
tings (plates), each group included three wells per setting.
Dendritic cell culture
DCs were generated from femoral BALB/c mice (Charles 
River, Sulzfeld, Germany) bone marrow, according to an 
approved protocol27 and in accordance with the German law on 
protecting animals (§4/03). The bone marrow was flushed with 
5 mL 4°C PBS out of the femur and centrifuged for 10 minutes 
at 290 g at 4°C. The supernatant was discarded to resuspend 
the cell pellet with RPMI 1640 (Biochrom, Berlin, Germany), 
which was supplemented with 10% fetal calf serum (FCS) 
and 50 µmol/L 2-mercaptoethanol (Sigma, Deisenhofen, 
Germany). A total amount of 2.5 × 106 cells was added to 
10 mL supplemented RPMI in a petri dish (Cell+; Sarstedt, 
Nümbrecht, Germany). Before cultivation at 37°C and 5% 
CO2, 20 ng/mL granulocyte-macrophage colony-stimulating 
factor (GM-CSF; R&D System, Minneapolis, MN) was added. 
On day 3, 10 mL of fresh medium containing 20 ng/mL GM-
CSF was added. On day 6 and 8, 10 mL of the culture media 
was removed and centrifuged to harvest the included cells. The 
cell pellet was resuspended in 10 mL of fresh media, which 
was supplemented with 20 ng/mL GM-CSF. On day 10, a 
number of 5 × 104 cells were seeded in 200 µL RPMI-media 
per well on a 96-multiwell plate. Rolipram (Tocris Bioscience), 
LNC–FITC–rolipram, LNC–FITC, and LNC–Blank were 
added in four concentrations (10 µM, n = 12; 1 µM, n = 12; 
0.1 µM, n = 12; 0.01 µM, n = 12). One hour after incubation 
with the test substances, DCs were stimulated with LPS to 
induce TNF-α production. After 24 hours, the supernatant was 
collected and the TNF-α concentration was measured using 
ELISA (R&D Systems, Minneapolis, MN).
In vivo study
Experimental animals
Female nonpigmented Dunkin Hartley guinea pigs (Charles 
River GmbH, Sulzfeld, Germany), weighing between 330–
460 g, were used. After confirmation of physiological hearing 
via acoustically evoked auditory brainstem response (AABR) 
measurement on day 0, the animals were systemically deaf-
ened. On day 7, in order to confirm deafness, AABR measure-
ment was repeated and animals were treated with LNC–FITC 
(n = 7), LNC–FITC–rolipram (n = 6), rolipram (n = 7), or PBS 
(n = 6; control group) via unilateral cochleostomy. Contralat-
eral PBS was applied as a control. After 3 weeks of deafness, 
animals were sacrificed for tissue harvesting.
The guinea pigs’ care and all experiments were carried 
out in accordance with the German law on protecting animals 
and were permitted by the regional government (LAVES, 
registration number 07/1266).
Anesthesia
Guinea pigs were anesthetized using medetomidine 
(0.3 mg/kg, Domitor®; Pfizer, Berlin, Germany) and   ketamine 
(40 mg/kg, Ketamin®; WDT, Garbsen, Germany) for elec-
trophysiological measurements and surgery. If necessary, 
animals received an additional injection of half of the origi-
nal dosage for surgery. On experimental day 21, after final 
AABR measurement, all animals received a second injection 
of the full dosage of anesthetics 15 minutes before sacrifice 
as described above. One hour before surgery, 0.05 mg/
kg atropine sulfate (B Braun Melsungen AG, Melsungen, 
Germany) and 5 mg/kg carprofen (Rimadyl®; Pfizer GmbH, 
Karlsruhe, Germany) were applied. Before surgery in the 
postauricular area and before perfusion in the region to be 
incised, local anesthesia was performed with prilocaine 
(Xylonest®;   AstraZeneca GmbH, Wedel, Germany).
Acoustically evoked auditory brainstem  
response measurement
AABR measurements were performed on day 0 to con-
firm the physiological hearing threshold of the animals. 
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  Hearing thresholds of #80 dB SPL at 1 kHz, #70 dB SPL 
at 4 kHz, #50 dB SPL, and #60 dB SPL at the middle 
  frequencies 8 kHz and 16 kHz, #70 dB SPL at 32 kHz, 
and #80 dB SPL at 40 kHz were set as thresholds for 
normal hearing. On day 7, AABR was measured again to 
verify the efficacy of the deafening procedure. A threshold 
shift of $50 dB or above 90 dB SPL was determined as 
deaf.28 On experimental day 21, a final measurement was 
carried out just before sacrifice. All AABR measurements 
were performed with a system (Tucker Davis Technolo-
gies,   Alachua, FL) that consisted of two RX6 multifunc-
tion processors, a loudspeaker driver unit (ED1), and two 
electrostatic speakers (EC1). The anesthetized animals 
were placed on a heating pad in a soundproof box where 
they were exposed to acoustic stimuli by electrostatic 
speakers (EC1) via modified ear tips. To record the neuro-
logical responses, four needle electrodes were subdermally 
implanted as follows: the reference electrode was attached 
to the nose, the auditory evoked potentials were derived via 
two electrodes relative to the left and right mastoid, and 
the ground electrode was placed on the neck to suppress 
interfering signals caused by heart rate or muscle tension. 
The recording electrodes were broadcasting the potentials 
of the low-impedance converter (RA4LI) to a preamplifier 
(RA4PA), which transferred a digitalized signal to the mul-
tifunction processor (RX6). Measurements were controlled 
by BioSigRP software (Tucker Davis   Technologies). The 
dynamic range of the stimuli (10 ms sinusoidal pulses; 
1 ms cosine-in and fade-out-function) was settled in 10 dB 
steps from 20–90 dB SPL, whereas frequencies of 1 kHz, 
4 kHz, 8 kHz, 16 kHz, 32 kHz, and 40 kHz were presented. 
In order to suppress background noise, bandpass filters 
were settled from 300 Hz to 3 kHz at 3 dB. In order to sup-
press other artifacts, a threshold of 70 µV was chosen. For 
graphical representation, each stimulus was repeated 270 
runs and averaged. The hearing threshold was determined 
by visual analysis as soon as a significant local maximum 
was observed in the course of the averaged wave.29
Deafening procedure
All animals were systemically deafened on day 0 using a 
common ototoxic procedure as described by Versnel and 
colleagues.30 After the preliminary AABR measurement, 
400 mg/kg kanamycine were injected subcutaneously. In the 
next two hours, the jugular vein was exposed under incision 
of the overlaying musculature in order to inject the loop 
diuretic furosemide (100 mg/kg). The coadministration of 
the aminoglycoside kanamycine with loop diuretics results 
in a complete loss of sensory cells, which initiates the 
degeneration of SGC. Before tissue harvesting, deafness was 
confirmed on day 7 and 21 by AABR measurement.
Application of the test substances
On day 7 of the experiments, animals were placed in ventral 
alignment on a heating pad after AABR measurement was 
performed in order to confirm the deafness of the animals. 
A postauricular incision was made under aseptic conditions. 
The overlying muscles were removed in order to examine 
the Bulla tympani, which was opened in the following step. 
Using a microscope (Carl Zeiss AG, Oberkochen, Germany), 
the cochlea was visualized in the opened middle ear cavity. A 
small hole was drilled under the use of a lancet in the basal 
turn of the cochlea and the scala tympani was opened. An 
injection catheter was assembled using a 27 G cannula (B 
Braun Melsungen AG) connected with a silicon tube (inner 
diameter 0.3 mm; LiquidScan GmbH and Co, KG, Überlin-
gen, Germany) and an inserted polyimide tube (inner diam-
eter 0.12 mm; Micro Lumen Inc, Tampa, FL) at the top. In 
order to avoid deep penetrations of the cochlea, a 2 mm sphere 
of carboxylate cement (ESPE Dental AG, Seefeld, Germany) 
was formed on the tip. The catheter was then inserted into 
the scala tympani to deliver a total volume of 5 µL of the 
test substances over a period of 5 to 10 minutes into the inner 
ear using a 10 µL Hamilton syringe (Hamilton Bonaduz 
AG, Bonaduz, Switzerland). The left ears were treated with 
the test substances (LNC–FITC [n = 7], rolipram [n = 6], 
LNC–FITC–rolipram [n = 7], and PBS [n = 6]) in a dilution 
of 1:100. As a control, the right ears were treated with PBS. 
Subsequently, the cochlea and the bulla tympani were sealed 
with carboxylate cement (Durelon®; ESPE Dental AG) and 
the soft tissue trauma was sutured in two layers.
Histological analysis
Anesthetized animals were sacrificed after final AABR mea-
surement on day 21 via transcardial perfusion by 200 mL PBS 
followed by 200 mL of paraformaldehyde (PFA; 4%; Merck, 
Darmstadt, Germany) infused in the left heart chamber. 
Cochleae were harvested and opened carefully at the apex 
and round window to exchange resisting perilymph for a 
fixative by slowly rinsing with 1 mL PFA (4%). Samples 
were placed in PFA for 2 hours for further fixation. Before 
decalcification, the cochleae were rinsed with PBS three 
times. Afterwards, they were placed in 20% EDTA (Sigma-
Aldrich Chemie GmbH, Steinheim, Germany) for 4–5 
weeks at 37°C. Decalcification media was changed every 
2 or 3 days. Before paraffin embedding, dehydration with 
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50%–100% ethanol (BÜFA Chemikalien, Altmoorhausen, 
Germany) was performed. 5 µm midmodiolar sections were 
generated from paraffin blocks, mounted on glass slides and 
stained with hematoxylin and eosin.
For analysis, all cochlea turns were identified with an Axio-
vert 25C Microscope (Carl Zeiss AG). The turns were named 
lower basal turn (lb), upper basal turn (ub), first middle turn 
(1 m), second middle turn (2 m), third middle turn (3 m), fourth 
middle turn (4 m), and apical turn (a) (Figure 2). Due to prepa-
ration methods, the 4 m and a turn could not always be analyzed 
separately. Therefore, the SGC densities of these areas, if 
available, were added for analysis. The first midmodiolar sec-
tion was selected randomly. Every fifth following section was 
chosen for analysis to ensure a separation of 25 µm between 
the sections. In total, five sections per cochlea were analyzed. 
Next to the perikaryal diameter, the number of   surviving SGC 
with a visible nucleus was examined. The number of surviving 
SGC in correlation to the measured cross-sectional area of 
the Rosenthal’s canal provides the SGC density, which can be 
expressed as cells/10.000 µm2. Soma diameter measurement 
was performed by dividing the area of each Rosenthal’s canal 
in four equal parts. In each part, two representative SGC were 
chosen for measurement. In case of less than eight surviving 
SGC, every visible cell was measured.
Statistical analysis
All data passed the normality test (Kolmogorov–Smirnov). 
Student–Newman–Keuls analysis of variance (ANOVA) was 
performed for in vitro data analysis. In vivo data were first 
analyzed using a paired t-test to compare the treated and 
Apex
a
4 m
3 m
2 m
Sc.vest 
*
1 m
M
ub
lb 
Sc.tymp 
AN
250.00 µm
Figure 2 representative midmodiolar hematoxylin and eosin-stained section (5 µm) of a deafened guinea pig cochlea. rosenthal’s canal areas are highlighted in red squares. 
Lower basal turn (lb), upper basal turn (ub), first middle turn (1 m), second middle turn (2 m), third middle turn (3 m), fourth middle turn (4 m), and apical turn (a) of the 
scala tympani are labeled. The arrow marks the cochleostomy where the solutions were injected into the scala tympani. The modiolus, the axis of the inner ear, and the 
apex, the upper part of the inner ears are marked. 
Note: *scala media.
Abbreviations: AN, auditory nerve; M, modiolus; Sc. tymp, scala tympani; Sc. vest, scala vestibuli (magnification: 40-fold).
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untreated ears of one animal group. Comparisons between 
the treated (left) ears of all groups, as well as the compari-
sons with the untreated (right) ears were performed using 
Student–Newman–Keuls ANOVA.
Results
SGC in vitro study – neuronal survival
SGC were seeded in a mean density of 1.5 × 104 cells/well. 
The seeding control was evaluated after 4 hours of cultivation 
and contained 229.6 ± 18.1 (mean ± standard deviation [SD]; 
n = 12) SGC. This was set as the reference value (100 %) for 
the experimental groups that were fixated after 48 hours. In five 
independently performed experimental settings (independent 
plates on different days), each group included 4–8 wells. 
Thus, each concentration of the test substances (1:50, 1:100, 
1:200, 1:300) was tested in a minimum of 20 wells. For BDNF 
treatment, 30 wells were used as positive control; for the 
untreated negative control, 12 wells were examined. Figure 3A 
depicts the mean and SD percentage of surviving SGC for each 
experimental group.
BDNF had the best results with a highly significant 
increased neuron survival in comparison to the negative control 
(45.7% ± 12.6% versus 10.7% ± 4.2%; P , 0.001), as well as 
compared to all other experimental groups (P , 0.001). Pure 
rolipram did not enhance neuronal survival. Homogenous 
values of 15.7% ± 4.5% survival rate in mean for each dilution 
of rolipram induced no significant difference when compared to 
the negative control, although a tendency toward an increased 
survival rate was visible. In combination with LNC, rolipram 
increased the neuronal survival in the 1:100 (32.6% ± 9.7%; 
P , 0.001) dilution. In comparison to the negative control, 
the 1:200 (23.4% ± 7.2%; P , 0.01) and 1:300 dilution 
(20.0% ± 6.4%; P , 0.05) proved to be neuroprotective as 
well. The 1:50 (16.2% ± 10.2%) dilution could not induce any 
benefits.
Treatment with unloaded LNC (FITC-labeled, but 
not containing rolipram) resulted in increased neuronal 
survival as well, though the effect was weaker than in 
the LNC–FITC–rolipram group. In this group, the 1:100 
(24.4% ± 8.8%; P , 0.001) and the 1:200 (20.7% ± 7.6%; 
P , 0.01) dilution showed positive effects.
Because LNC–FITC nanoparticle treatment resulted in 
increased neuronal survival, an additional test was performed 
to evaluate which nanoparticle component – the nanoparticle 
itself or the fluorescein FITC – has neuroprotective prop-
erties. The results revealed neuroprotective effects of the 
particle itself. As shown in Figure 4, LNC–Blank particles 
significantly increased the survival rate in comparison to the 
negative control.
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Figure 3 (A) Survival rates of cultured SGC treated with LNC–FITC, LNC–FITC–
rolipram,  rolipram,  and  BDNF  in  different  concentrations.  rolipram  was  used  in 
concentrations of 38 ng (1:50 dilution; n = 5; total: 20 wells), 19 ng (1:100 dilution; 
n = 5; total: 20 wells), 9.5 ng (1:200 dilution; n = 5; total: 20 wells), and 6.3 ng (1:300 
dilution; n = 5; total: 20 wells) per 0.1 mL medium. Stock solution of LNC contained 
45  mg/mL  FITC  (4.2  ×  1015  LNC/mL).  LNC–FITC–rolipram  particles  contained 
19 µg/mL rolipram. BDNF (50 ng/mL, n = 5; total: 30 wells) served as positive control. 
(B)  Neurite  outgrowth  of  cultured  SGC  treated  with  LNC–FITC,  LNC–FITC–
rolipram, rolipram, and BDNF in different concentrations (mean ± SD). LNC–FITC 
1:50 decreased the SGC–neurite length highly significantly (P , 0.001) compared 
to all other experimental groups (not marked in the graph) except the LNC–FITC–
rolipram 1:50 group (P , 0.01; left upper line). Significant differences among treatment 
groups compared to the negative control are marked above the columns.
Notes: *P , 0.05; **P , 0.01; ***P , 0.001.
Abbreviations:  BDNF,  brain-derived  neurotrophic  factor;  FITC,  fluorescein 
isothiocyanate;  LNC,  lipidic  nanocapsules;  SD,  standard  deviation;  SGC,  spiral 
ganglion cells.
SGC in vitro study: neurite lengths
Neurite lengths of the negative control were measured with 
a mean of 420.1 ± 181.5 µm (mean ± SD). BDNF and 
rolipram did not influence the neurite outgrowth, whereas the 
1:50 dilutions of the LNC–FITC (265.6 ± 159.4 µm; P , 0.001) 
and LNC–FITC–rolipram group (349.3 ± 178.3 µm; 
P , 0.05) induced significantly decreased neurite lengths. 
In comparison to the negative control, LNC–FITC showed 
a positive effect on the neurite lengths in the 1:300 dilution 
(519.1 ± 205.4 µm; P , 0.05), LNC–FITC–rolipram in the 
1:100 (547.6 ± 164.1 µm; P , 0.01), and 1:200 dilution 
(536.8 ± 201.1 µm; P , 0.01), whereas the other dilutions 
did not differ from the negative control (Figure 3B).
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average cell diameter of the negative control. Values are 
shown in Table 1.
DC in vitro study – TNF-α inhibition
Per well 5 × 104 DCs were seeded. For each concentration 
and experimental group, four wells were performed per 
plate. Three repeated settings resulted in a total of 12 wells 
per concentration and group.
The TNF-α production of all rolipram-treated DC was 
significantly inhibited when compared to the positive control 
(338.18 ± 41.82 pg TNF-α/mL; mean ± SD). The inhibi-
tion was dose-dependent: higher rolipram concentrations 
induced higher TNF-α suppression (Figure 5). A similar 
decrease was shown in the LNC–FITC–rolipram-treated 
group, though the values demonstrated a weaker inhibition 
of the TNF-α production. LNC–Blank nanoparticles caused 
a slight inhibition of the cytokine in the concentration of 
1 µM (283.11 ± 23.01 pg/mL; P , 0.05). A strong decrease 
of TNF-α secretion was caused by LNC–Blank particles with 
the concentration 10 µM (98.11 ± 81.29 pg/mL; P , 0.001). 
The LNC–FITC nanoparticles showed resembling char-
acteristics when compared to the LNC–Blank particles 
with a very strong inhibition in the 10 µM concentration 
(146.90 ± 7.64 pg/mL; P , 0.001). By microscopic exami-
nation of the DC culture, granulation and misshaping of the 
cells in the 10 µM nanoparticles groups (LNC–Blank, LNC–
FITC, LNC–FITC–rolipram) was observed. Cell vitality 
tests confirmed toxic effects in these concentrations (data in 
Supplementary materials).
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Figure 4 Survival rates of cultured SGC treated with LNC–FITC and LNC–Blank   
in different concentrations (n = 9 for each group, mean ± SD). Stock solution of 
LNC contained 45 mg/mL FITC (4.2 × 1015 LNC/mL). BDNF (50 ng/mL, n = 9) 
served as positive control. The SGC survival rate of all experimental groups differed 
significantly from the survival rates of neurons treated with BDNF (upper horizontal 
line; *P , 0.05; **P , 0.01; ***P , 0.001). Statistically significant differences of LNC 
(with and without FITC)-treated SGC compared to the negative control are marked 
above the respective column.
Abbreviations:  BDNF,  brain-derived  neurotrophic  factor;  FITC,  fluorescein 
isothiocyanate;  LNC,  lipidic  nanocapsules;  SD,  standard  deviation;  SGC,  spiral 
ganglion cells.
Table 1   results  of  the  measured  soma  diameter  of  SGC 
(mean ± SD) after 48 hours cultivation with LNC–FITC, LNC–
FITC–rolipram, rolipram, or BDNF in the shown concentrations
Experimental group Mean soma  
diameter  
[μm]
SD Number of   
measured  
somae
Negative control 14.5 2.6 60
LNC–FITC 1:50 12.8 1.9 100
LNC–FITC 1:100 13.2 2.2 100
LNC–FITC 1:200 13.3 2.2 100
LNC–FITC 1:300 14.0 3.2 100
LNC–FITC–rolipram 1:50 13.3 2.1 100
LNC–FITC–rolipram 1:100 14.0 2.6 100
LNC–FITC–rolipram 1:200 13.7 2.8 100
LNC–FITC–rolipram 1:300 14.1 3.0 100
rolipram 1:50 14.4 2.6 100
rolipram 1:100 14.7 2.9 100
rolipram 1:200 14.6 3.0 100
rolipram 1:300 14.6 3.1 100
BDNF 50 ng/mL 14.8 2.7 130
Abbreviations:  BDNF,  brain-derived  neurotrophic  factor;  FITC,  fluorescein 
isothiocyanate; LNC, lipidic nanocapsules; SGC, spiral ganglion cells.
SGC in vitro study: soma diameter
The mean soma diameter of the negative control was 
14.5 ± 2.6 µm (mean ± SD, n = 60). Only the cell diameter 
of the 1:50 LNC–FITC (stock solution: 45 mg/mL LNC)-
treated SGC showed a significant decrease in soma diameter 
(12.8 ± 1.9 µm; P , 0.01). None of the other groups provided 
statistically significant differences when compared with the 
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Figure 5 TNF-α-secretion of DCs treated with rolipram, LNC–FITC–rolipram, 
LNC–Blank, and LNC–FITC in different concentrations. DC were stimulated with 
LPS 1 hour after incubation with the test substances. Data show mean ± SD from 
three independent experiments: each consisted of n = 12 wells per concentration 
per group. Statistically significant differences in TNF-α secretion compared to the 
LPS-control group are plotted above the columns. 
Notes: *P , 0.05; **P , 0.01; ***P , 0.001.
Abbreviations:  BDNF,  brain-derived  neurotrophic  factor;  DC,  dendritic  cells; 
FITC, fluorescein isothiocyanate; LNC, lipidic nanocapsules; SD, standard deviation; 
SGC, spiral ganglion cells; TNF-α, tumor necrosis factor-α.
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In vivo results
AABr measurements
To determine the hearing threshold, animals underwent 
AABR measurements on day 0, 7 and 21 of the study.
A preliminary AABR was performed just before the 
  systemic deafening on day 0 to confirm the physiological hear-
ing property of the animals. At 1 kHz, the threshold was shown 
at 72.90 ± 12.43 dB SPL, at 4 kHz 61.44 ± 12.55 dB SPL, 
at 8 kHz 36.14 ± 11.62 dB SPL, at 16 kHz 48.86 ± 11.76 dB 
SPL, at 32 kHz 49.02 ± 9.85 dB SPL, and at 40 kHz 
63.91 ± 13.61 dB SPL (graphed in Supplementary material). 
The mean difference between the left and the right ear was 
5.13 dB. The generated data showed normal hearing physiol-
ogy of the tested animals according to previous studies.
The AABR measurements on day 7 and 21 were per-
formed to confirm the deafening procedure. In no case of 
the measured frequencies was a positive AABR waveform 
visible until the measuring limit of 90 dB SPL. According 
to the literature, a threshold shift of 50 dB confirmed a suc-
cessful deafening procedure.28
SGC densities in vivo
No significant differences concerning the SGC densities 
were observed when the data from the treated left ears were 
compared (Figure 6A). The same results occurred when the 
SGC densities of the right ears were compared. Furthermore, 
the paired t-test revealed no differences between the right 
and left ears within the test groups. Only the SGC-densities 
of the left and right ears of the PBS-control group varied 
significantly (4.14 SGC ± 1.40/ 10.000 µm2; mean ± SD 
versus 5.23 SGZ ± 1.67/ 10.000 µm2; P , 0.05; Figure 6A). 
Representative images of Rosenthal’s canal of all four treat-
ment groups are shown in Figures 7A–D.
SGC diameter in vivo
Soma size was measured to evaluate the effect of the test 
substances on the cellular size. The LNC–FITC group 
showed a significant increase of the soma diameter between 
the left treated and the right control ears (14.00 ± 0.76 µm 
[mean ± SD] versus 13.14 ± 0.52 µm; P , 0.05). An even 
more evident increase of soma diameter was observed 
between the left and right ear of the rolipram-treated animals 
(13.78 ± 0.26 µm versus 12.73 ± 0.32 µm; P , 0.01). The 
SGC diameter in the LNC–FITC–rolipram group (left: 
13.91 ± 1.33 µm versus right. 12.68 ± 0.72 µm) and the 
PBS control group (left: 13.27 ± 0.56 µm versus right: 
12.68 ± 0.79 µm) did not differ significantly, although a dif-
ference by trend might be assumed (Figure 6B). There were 
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Figure 6 (A) Mean SGC density (cells/10.000 µm2) of deafened guinea pigs treated 
with LNC–FITC (n = 7), LNC–FITC–rolipram (n = 6), rolipram (n = 7), and PBS 
(n = 6) in 1:100 dilution (mean ± SD; *P , 0.05). (B) Mean SGC soma diameter of 
deafened guinea pigs treated with LNC–FITC, LNC–FITC–rolipram, rolipram, and 
PBS in 1:100 dilution (mean ± SD; *P , 0.05; **P , 0.01). Only LNC–FITC- and 
rolipram-treated animals showed a significant difference in SGC soma diameters 
between left (le, test substance) and right (ri, control).
Abbreviations: FITC, fluorescein isothiocyanate; LNC, lipidic nanocapsules; PBS, 
phosphate-buffered saline; SD, standard deviation; SGC, spiral ganglion cells.
no significant differences when the soma diameter of the left 
ears of all groups were compared. The same data unity was 
observed when comparing the right ears of all groups.
Discussion
This study demonstrates that BDNF (50 ng/mL) shows the 
most effective neuronal protection regarding the survival rate 
of cultured SGC. Former studies already confirmed a maxi-
mum survival rate of SGC with BDNF in this   concentration.31 
Due to that property, BDNF was chosen as a positive con-
trol, although the main focus was on the examination of the 
neuroprotective effects of rolipram and in LNC-incorporated 
rolipram.
Pure administration of rolipram demonstrated no efficient 
SGC protection in vitro in any of the used concentrations. 
This might be due to the intracellular mechanism of phos-
phodiesterase-4 inhibitors. Rolipram has to be translocated 
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Figure 7 (A–D) representative images of guinea pigs’ rosenthal’s canals 21 days after deafening. (E) illustrates the SGC density in normal hearing animals as compared to 
the deafened ones in (A–D) (the picture is from a previous experiment registered at LAVES with the same registration number as the experiments described here: 07/1266). 
(A) is from an animal from the LNC–FITC group receiving the nanoparticle in a 1:100 dilution (stock solution 45 mg/ml LNC). (B) represents the rosenthal’s canal of animals 
treated with LNC–FITC–rolipram (1:100 dilution of 45 mg/mL LNC and 19 µg/mL rolipram in stock solution) and (C) is from an animal that received rolipram (1:100 dilution 
of 19 µg/ml rolipram stock solution). An image of rosenthal’s canal from the control group is shown in (D).
Notes: In each picture, an arrows point to one representative vital SGC. Magnification: 200-fold.
Abbreviation: SGC, spiral ganglion cells.
in the cytoplasm where phosphodiesterase 4 is located. Once 
in the cytoplasm, rolipram inhibits phosphodiesterase 4, 
which leads to increased levels of cyclic adenosine mono-
phosphate (cAMP). Proteinkinase A, which depends on 
cAMP, phosphorylates cAMP responsive   element   binding 
protein (CREB) in the cellular nucleus.32 The activated 
CREB triggers the transcription of BDNF,33 which leads to a 
neuroprotective effect. To induce this effect, the application 
of rolipram via LNC was chosen to enhance the intracel-
lular concentration of rolipram, which subsequently leads 
to neuronal protection.
Results confirm an increased SGC survival rate using the 
LNC–rolipram combination. The dilution of 1:100 showed 
the best results in vitro, therefore this dilution was used for in 
vivo experiments as well. Decreasing effects of the 1:200 and 
1:300 dilutions are probably caused by low concentrations, 
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whereas the 1:50 dilution may have a toxic effect on cellular 
metabolism. Recent studies lead to the assumption that 
mutual reactions between the phospholipids of the particle 
shell and the cell membrane may cause an imbalance in 
endo- and exocytotic reactions.34 This consideration refers 
to former   observations revealed in a study with polylysine 
nanoparticles.35 Another experiment also shows good bio-
compatibility of the lipid nanocapsules on fibroblast cultures. 
Cytotoxic effects occurred only above a concentration of 
2.2 mg/mL.36 Our own observations revealed the effects of 
decreased SGC survival already in the 1:50 dilution (0.9 mg/
mL), suggesting that neuronal cells are more metabolically 
sensitive.
The synergistic effect of rolipram and the nanoparticle is 
evident; the pure administration of rolipram did not signifi-
cantly affect the SGC survival.
It is important to note that we found a distinct neuropro-
tective effect of the unloaded LNC–FITC particles as well. 
Compared to the LNC–FITC–rolipram combination, the SGC 
survival was significantly lower, which must be caused by 
the payload rolipram; hence the experimental groups differ 
only in this characteristic. To verify whether the nanoparticle 
itself or the fluorescein FITC are responsible for the neuro-
protective effect of the drug-unloaded LNC–FITC particles, 
an additional SGC culture experiment was performed with 
FITC-unlabeled LNC. The results prove that the particle 
itself is responsible for the neuroprotective effects. We 
hypothesize that the positive effect of the unloaded particles 
is caused by the particle component PEG. Inserted into the 
particle shell, this polymer protects the drug-delivery system 
against the complement system of the organism to maintain 
a prolonged circulation time in the body.37,38 Furthermore, 
PEG is used for the covalent binding of FITC.
Former experiments demonstrated the neuroprotective 
effects of PEG in dogs suffering from intervertebral disc 
prolapse.39 Other studies with spinal cord injury models 
confirmed the beneficial effects of PEG; damaged cells were 
literally sealed by this polymer.40 Thus, it is remarkable that 
our LNC are neuroprotective themselves and are appropriate 
for delivering drugs, such as rolipram, to target cells in vitro 
to significantly increase this protective effect.
After primary hair cell loss, a progressive decrease of 
neurite length and SGC density is observed.41 To ensure 
an optimal electrical stimulation via cochlear implants, 
neurite preservation and, if possible, outgrowth is desired. 
Therefore, we measured the SGC neurite length in vitro 
to evaluate their outgrowth depending on the different test 
conditions. Rolipram did not affect the neurite outgrowth 
of SGC in any of the applied concentrations. Because of 
rolipram inhibiting phosphodiesterase 4 in the cytoplasm 
of cells, we hypothesize that the drug was not taken up by 
the neurons and therefore was not able to induce a biologi-
cal effect on SGC. In contrast to this, an elongation of the 
neurite outgrowth was demonstrated when SGC were treated 
with rolipram encapsulated in LNC–FITC nanoparticles. 
The 1:100 and 1:200 dilutions of the LNC–FITC–rolipram 
particles increased the neurite outgrowth significantly. 
This is an indirect indication of LNC-mediated improved 
rolipram uptake into SGC. Next to this, cells treated with 
LNC–FITC 1:300 revealed a significant neurite outgrowth 
as well, probably due to the PEG component, as described 
before concerning neuronal survival. Higher concentrations 
(1:50 dilution) of both experimental groups induced rather 
short neurites, which indicates negative effects on the SGC. 
The rolipram-induced mechanism on neurite elongation is 
not clearly discovered, though a cAMP-dependent activation 
of protein kinase A might be involved.42 Taking this, our 
findings support Xu et al’s report concerning the biphasic 
effect of the cAMP analog cpt-cAMP on neurite length. They 
were able to show an increased length at lower concentra-
tions and reduced length at higher concentrations.43 On the 
other hand, in the present study, rolipram-loaded nanopar-
ticles significantly elongated the neurites in 1:50 dilution 
when compared to the unloaded LNC in 1:50 dilution. One 
could speculate that this divergence is based on the rolipram 
and that this finding supports the hypothesis that rolipram 
positively affects neurite outgrowth. Until recently, limited 
research was available on rolipram effects and mechanisms 
of effects on neuronal cells. Further studies are necessary to 
confirm or refute the hypotheses.
Results of the perikaryal diameter showed no significant 
differences between the experimental groups except the SGC 
treated with 1:50 LNC. High concentration of LNC might 
induce negative effects on the cell metabolism, as described 
before, which influences the cell diameter.
The preincubation of DC with rolipram caused a highly 
significant, dose dependent inhibition of TNF-α secretion in 
all tested concentrations (0.01 µM, 0.1 µM, 1 µM, 10 µM) 
after stimulation with LPS. The collected data are in accor-
dance with the results of a former study,34 which reported 
a dose-dependent reduction of LPS stimulated human DC 
with rolipram as well. The LNC–FITC–rolipram combination 
shows a similar dose-dependent decrease of TNF-α, though 
the weaker effects in comparison to the pure administration 
might be caused by an insufficient release of the payload in 
the incubation time of 24 hours. Other LNC groups showed 
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no or rather weak TNF-α inhibition in the concentrations of 
0.01 µM, 0.1 µM, and 1 µM. Upon microscopic examination, 
nanoparticle concentrations of 10 µM caused toxic effects on 
the cells. Granulated and misshaped cells, as well as crystal 
formations, were also visible. Thus, the low concentrations of 
TNF-α in these experimental groups are caused by decreased 
cellular vitality and not by an TNF-α inhibition, which was 
confirmed by a cell vitality test (CellTiter 96® AQueos One 
Solution Cell Proliferation Assay; Promega, Madison, WI; 
see Supplementary material).
By reducing the TNF-α transcription through cAMP-
dependent protein kinases,44 rolipram can alleviate inflam-
mations, hence TNF-α plays a key role in proinflammatory 
processes. In combination with cochlear implants, benefits 
may be achieved by inhibiting postinsertion inflammation 
processes.
Our data proves that rolipram penetrates the DC cell 
membrane and evokes biological responses in this cell type. 
Conversely, rolipram does not cause a biological reaction in 
SGC without the support of the tested drug-delivery system 
LNC. Even if a small amount of pure rolipram can influence 
neuronal cells, the encapsulation in nanocarriers would be 
beneficial. As LNC encapsulation of rolipram increases the 
SGC survival rate and would allow a targeted drug delivery 
in future, this approach would be economically and clinically 
beneficial in terms of lower costs for drugs and decreasing 
side effects.
The positive results of in vitro experiments, which 
provided the basis for the performed in vivo studies, could 
not be confirmed in vivo. The comparison between the test 
substance-treated left ears with the right control ears (PBS-
treated) revealed no differences in SGC-densities. The only 
significant difference was shown in the control group, where 
both sides were inoculated with PBS.
These results might be caused by an additional peri-
lymphatic dilution of the test substances which leads to an 
ineffective concentration. In future experiments, the neuro-
protective effect of a higher dosage of LNC rolipram particles 
might be examined, although the risk of causing toxic effects 
on the neuronal cells is a possibility. By administrating high 
dosages at the base of the cochlea, basal cells could be influ-
enced by the high concentration before the desired dilution is 
achieved in the whole cochlea volume. Furthermore, a leak-
age of the injected substances via the ductus perilymphaticus 
is assumed since a contralateral transfer between treated and 
untreated cochleae was confirmed.45
Another reason for the different results of the in vitro 
and in vivo study may be the usage of different species of 
different ages. On the one hand, neonatal rats were used to 
perform the in vitro culture; on the other hand, adult guinea 
pigs were used for in vivo studies. Thus, different trophic 
requirements and receptor expressions for neonatal and adult 
SGC were presumed, which are likely to differ in the young 
and adult stage.9 The inhomogeneous results might be due 
to an inadequate trophic support in the adult stage of the 
in vivo experiment.
Regarding the increased SGC degeneration following the 
cessation of neurotrophic factors,9 a preliminary protection 
could be assumed for the test substances used in this study. 
By performing single administration, the neuroprotective 
effect might be achieved in the first period of the study. The 
positive effect could be distinguished after the accelerated 
degeneration, as described by Gillespie and colleagues.9 
A later experiment could not reproduce the effect of an 
increased SGC degeneration after cessation of neurotrophic 
factors, whereas electrical stimulation for hearing threshold 
measurements was performed,28 which themselves have 
neuroprotective potential.46,47
As mentioned before, the only significant difference in 
SGC density in vivo was detected between the PBS-treated 
ears of the control group. Considering that the SGC density 
of both ears should be equal because of equal treatment, one 
could speculate that the difference is based on an additional 
trauma due to PBS injection and manipulation that increases 
the deafness-induced SGC degeneration at the left side. The 
surgeon’s handedness could also be an explanation for this. 
But the left ears’ SGC density was the same as one of the other 
experimental groups. Additionally, the SGC density of PBS-
treated right ears of the PBS group was higher than the density 
of all other PBS-treated right ears of the other experimental 
groups. Therefore, it is not an increased SGC degeneration 
in left PBS-treated ears of the control group but a decreased 
SGC degeneration in right PBS-treated ears of the PBS group. 
We do not yet have an explanation for this effect.
We were able to demonstrate significantly increased soma 
diameters of the treated ears in the LNC–FITC group and the 
rolipram group in vivo. In the LNC–FITC–rolipram group, 
the SD’s soma diameter was relatively wide and, even if the 
graph (Figure 6B) looks like there may be a significant dif-
ference between the treated and nontreated ears of this group, 
no statistically significant difference was observed. Several 
previous studies reported an increase of soma diameter after 
treatment with neurotrophic factors such as BDNF in deafened 
animals.48,49 The underlying mechanisms of the soma diameter 
increase and the functional impact are not yet known, which 
complicates a final appraisal of this parameter.
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Conclusion
This study demonstrates the SGC protective effects of LNC-
mediated rolipram delivery in vitro in terms of concentration 
dependent neuronal survival and neurite outgrowth. 
We hypothesize that this biological effect indirectly 
demonstrates that the lipidic nanoparticles improve the trans-
port of rolipram through the neuronal cell membrane into the 
cytoplasm of the neurons where the increase of rolipram and 
LNC induces significant neuronal protection. Additionally, 
we were able to demonstrate a strong anti-inflammatory effect 
of rolipram when cultivated with activated dendritic cells. The 
LNC rolipram combination presented an anti-inflammatory 
effect as well, though weaker, which might be due to the 
release rate of rolipram out of the LNC.
The in vivo study did not confirm the in vitro results, 
which might be due to either perilymphatic dilution or insuf-
ficient duration of drug application.
Even if the in vitro results that we were able to report 
on could not be confirmed in vivo, we still believe that 
rolipram is a promising drug for neuronal protection in 
inner ear therapy and that LNC are a feasible drug-delivery 
system for treatment of inner ear cells if in vivo methods 
are modified. Future work has to thoroughly investigate the 
effect of LNC on SGC and DC, and has to identify the cor-
rect LNC/rolipram ratio to cause a biological effect in vivo. 
Additionally, experiments may be conducted to investigate 
the effect of LNC/rolipram on connective tissue proliferation 
around an implanted device in vivo. Controlled uptake of 
LNC into cochlear cells should be investigated to decrease 
the amount of LNC that have to be applied. Nevertheless, 
at present, LNC are promising tools to deliver drugs to the 
inner ear since they are non-toxic to the inner ear tissue in 
vitro and in vivo if applied in sufficient dilution. They also 
enable the biological effect of rolipram in vitro. This opens 
the exciting possibility of using these nanoparticles as a 
drug-delivery system for inner ear structures.
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Supplementary material
Vitality test
To determine the vitality of dendritic cells at the end of the 
experiment (day 10), a CellTiter 96® Aqueous One Solution Cell 
Table S1 Vitality values of dendritic cells after incubation with 
the test compounds and LPS stimulation; n = 3 per substance and 
concentration
rolipram 0.01 μmol 0.414 0.399 0.391
rolipram 0.1 µmol 0.406 0.419 0.417
rolipram 1 µmol 0.4 0.413 0.423
rolipram 10 µmol 0.421 0.367 0.433
LNC–FITC–rolipram 0.01 µmol 0.502 0.399 0.416
LNC–FITC–rolipram 0.1 µmol 0.411 0.374 0.438
LNC–FITC–rolipram 1 µmol 0.446 0.499 0.455
LNC–FITC–rolipram 10 µmol 0.922 0.84 0.784
LNC–Blank 0.01 µmol 0.497 0.482 0.476
LNC–Blank 0.1 µmol 0.42 0.431 0.418
LNC–Blank 1 µmol 0.493 0.451 0.463
LNC–Blank 10 µmol 0.172 0.249 0.186
LNC–FITC 0.01 µmol 0.497 0.422 0.396
LNC–FITC 0.1 µmol 0.429 0.42 0.359
LNC–FITC 1 µmol 0.519 0.474 0.446
LNC–FITC 10 µmol 0.67 0.654 0.619
DMSO (vehicle control) 0.32 0.319 0.322
LPS (positive control) 0.518 0.465 0.444
Notes: Data are shown in relative values and reflect the optical density. High scores 
correlate with an undisturbed cell vitality. The values of the LNC–FITC 10 µmol and 
LNC–FITC–rolipram 10 µmol groups are the highest, even though the cells were 
certainly destroyed. The influence of the fluorescence marker FITC in this high 
concentration is responsible for these false positive results.
Abbreviations: DMSO, dimethyl sulfate; FITC, fluorescein isothiocyanate; LNC, 
lipidic nanocapsules; LPS, lipopolysaccharide.
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Figure S1 By frequency-specific AABR measurements on day 0, a normal hearing threshold was detected in all animals (blue and pink line; mean ± SD).
Notes: The results of the measurements on day 7 and day 21 are plotted as a red line. None of the animals had residual hearing after the deafening procedure. The hearing 
threshold of all animals was 90 dB SPL or above on day 7 and did not recover until the final measurement on day 21.
Abbreviations: AABr, acoustically evoked auditory brainstem response; SD, standard deviation.
Proliferation Assay (Promega, Madison, WI) was   performed. 
In addition, the cells were subjected to microscopic inspec-
tion to note any morphological   differences. This examination 
allows a trend statement about a possible influence of the test 
substances. The results of the viability test reveal possible cel-
lular impairments caused by the test substances. Thus, a lower 
production of tumor necrosis factor-α (TNF-α) depends not 
only on the inhibition of cytokine production but also on an 
increased degeneration of cells. This assay is based on nicoti-
namide adenine dinucleotide phosphate (NADPH) and nico-
tinamide adenine dinucleotide (NADH), which catalyzes the 
conversion of the yellow methyltetrazolium to a violet formazan 
product. NADPH/NADH are only found in living cells. Con-
sequently, a color change by 490 nm measured by photometric 
analysis is an indication of cell vitality. The resulting amount of 
formazan is directly proportional to the number of viable cells. 
Supplementary Table 1 shows the measured values.
AABr measurements
Acoustically evoked auditory brainstem response measure-
ments were performed to determine the hearing threshold 
of all experimental animals before and after deafening for 
verification of the procedure’s success. Because the used 
system allows stimulation with a maximum of 90 dB SPL 
and all animals’ hearing thresholds reached or exceeded that 
level 7 and 21 days after deafening, the hearing thresholds 
are plotted at 90 dB (Supplementary Figure 1).
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